이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

CanSino Biologics 배당금

배당금 기준 확인 0/6

CanSino Biologics 현재 배당금을 지급하지 않습니다.

주요 정보

배당 수익률

지급 비율

업계 평균 수익률	1.1%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-HK$6.13
3년 후 배당 수익률 예측	0%

최근 배당금 업데이트

Recent updates

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

Jun 20

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Apr 07

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Feb 06

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Oct 13

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Sep 07

Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts

Jul 13

Is CanSino Biologics (HKG:6185) Using Too Much Debt?

Jul 01

We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt

Mar 15

CanSino Biologics Inc. (HKG:6185) Analysts Just Slashed Next Year's Revenue Estimates By 15%

Jan 11

Are Investors Undervaluing CanSino Biologics Inc. (HKG:6185) By 20%?

Dec 26

CanSino Biologics (HKG:6185) Seems To Use Debt Quite Sensibly

Oct 01

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 6185 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: 6185 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

CanSino Biologics 시장 대비 배당 수익률

6185 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (6185)	0%
시장 하위 25% (HK)	3.4%
시장 상위 25% (HK)	8.0%
업계 평균 (Biotechs)	1.1%
3년 후 애널리스트 예측 (6185)	0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 6185 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 6185 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 6185 Hong Kong 시장에서 주목할만한 배당금을 지급하지 않습니다.

주주에 대한 현금 배당금

현금 흐름 범위: 6185 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

CanSino Biologics 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Cansino Biologics Inc. Announces Dividend for the Financial Year Ended December 31, 2021 Payable on 19 August 2022

Cansino Biologics Inc. Proposes Dividend for the Financial Year Ended 31 December 2021

Recent updates

CanSino Biologics Inc. to Report First Half, 2024 Results on Aug 30, 2024

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

CanSino Biologics Inc., Annual General Meeting, Jun 27, 2024

CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee

Consensus EPS estimates upgraded to CN¥1.19 loss

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Cansino Biologics Inc. Announces Positive Preliminary Results from Phase I Clinical Trials of the Protein-Based Pneumococcal Vaccine

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Full year 2023 earnings: EPS and revenues miss analyst expectations

CanSino Biologics Inc. to Report Q1, 2024 Results on Apr 30, 2024

Consensus EPS estimates upgraded to CN¥1.04 loss, revenue downgraded

Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine

Full year 2023 earnings: EPS and revenues miss analyst expectations

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023

CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine

Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Enrollment for TDCP Adolescent and Adult

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case

Third quarter 2023 earnings released

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Second quarter 2023 earnings released: CN¥2.82 loss per share (vs CN¥0.44 loss in 2Q 2022)

New minor risk - Share price stability

CanSino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc. Announces CS-2032 Zoster Vaccine Obtains Clinical Trial Approval from Canada

CanSino Biologics Inc. to Report First Half, 2023 Results on Aug 22, 2023

Cansino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc., Annual General Meeting, Jun 30, 2023

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Full year 2022 earnings released: CN¥3.65 loss per share (vs CN¥7.74 profit in FY 2021)

Consensus EPS estimates fall by 49%

CanSino Biologics Inc. Provides Earnings Guidance for the Period from January 1, 2022 to December 31, 2022

Non-Executive Director recently sold HK$3.4m worth of stock

Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?

Cansino Biologics Inc. Announces Covid-19 Mrna Vaccine Cs-2034 Achieved Positive Interim Data in A Clinical Trial Evaluating the Safety and Immunogenicity of the Heterologous Cs-2034 Booster

CanSino Biologics Inc. Announces Clinical Research Results of A Clinical Trial of Bivalent Recombinant Covid-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation in Adults Aged 18 Years and Above

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

Less than half of directors are independent

CanSino Biologics Inc.'s Recombinant Covid-19 Vaccine (Adenovirus Type 5Vector) for Inhalation Approved for Emergency Use in Morocco

Consensus EPS estimates fall by 73%

Consensus revenue estimates fall by 12%

Now 38% undervalued

Third quarter 2022 earnings released

Investor sentiment improved over the past week

CanSino Biologics Inc. to Report Q3, 2022 Results on Oct 28, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up

CanSino Biologics Inc. Recombinant Covid-19 Vaccine for Inhalation Included for Emergency Use as A Booster Vaccine in PRC

Consensus revenue estimates fall by 41%

Investor sentiment deteriorated over the past week

Things Look Grim For CanSino Biologics Inc. (HKG:6185) After Today's Downgrade

Should You Be Adding CanSino Biologics (HKG:6185) To Your Watchlist Today?

Second quarter 2022 earnings released: CN¥0.44 loss per share (vs CN¥3.67 profit in 2Q 2021)

CanSino Biologics Inc. to Report Q2, 2022 Results on Aug 26, 2022

Investor sentiment deteriorated over the past week

Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts

Consensus revenue estimates fall by 12%

Is CanSino Biologics (HKG:6185) Using Too Much Debt?

Cansino Biologics Inc. Announces Dividend for the Financial Year Ended December 31, 2021 Payable on 19 August 2022

Investor sentiment improved over the past week

CanSino Biologics Inc., Annual General Meeting, Jun 29, 2022

CanSino Biologics Inc., Annual General Meeting, Jun 29, 2022

CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

CanSino Biologics Inc. to Report Q1, 2022 Results on Apr 28, 2022

Investor sentiment deteriorated over the past week